Raymon Heather 4
4 · Artiva Biotherapeutics, Inc. · Filed Dec 12, 2025
Insider Transaction Report
Form 4
Raymon Heather
SVP, Research and Development
Transactions
- Award
Common Stock
2025-12-12+67,253→ 106,844 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−18,239→ 0 totalExercise: $5.14Exp: 2030-11-02→ Common Stock (18,239 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−12,539→ 0 totalExercise: $5.01Exp: 2033-04-02→ Common Stock (12,539 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−14,819→ 0 totalExercise: $5.01Exp: 2033-04-02→ Common Stock (14,819 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−11,399→ 0 totalExercise: $5.18Exp: 2034-01-23→ Common Stock (11,399 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−10,259→ 0 totalExercise: $13.47Exp: 2034-05-01→ Common Stock (10,259 underlying)
Footnotes (7)
- [F1]Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs").
- [F2]On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I.
- [F3]25% of the shares vested on October 22, 2021, and the remaining shares vest in 36 equal monthly installments thereafter.
- [F4]25% of the shares vested on January 1, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.
- [F5]25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
- [F6]Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts.
- [F7]25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.